Omnibus bill includes $3.1 billion for dementia research
By
Lois A. Bowers
Dec 22, 2020
The $1.4 trillion appropriations omnibus spending bill advanced by congressional leaders on Monday includes an increase of more than $300 million in funding for dementia research at the National Institutes...
Inverse link found for antioxidant levels, all-cause dementia
May 04, 2022
Serum lutein+zeaxanthin and β-cryptoxanthin levels were inversely associated with incident all-cause dementia.
Caregivers, seniors with Alzheimer’s to benefit from ‘Rippl’ effect, access to 24/7 helpline
By
Aaron Dorman
Apr 09, 2024
A new dementia care platform will get telehealth to more seniors, and their caregivers, including access to a 24/7 helpline.
Master Plan for Aging adds dementia screening tool for providers
By
Lois A. Bowers
Apr 17, 2023
Primary care providers in the country’s most populous state have a new screening tool to help them identify cognitive decline in older adults and determine next steps.
Inconsistent state regulations, staff training produce wide variations among states’ antipsychotic...
By
Kimberly Bonvissuto
Feb 28, 2023
Researchers are calling for a closer look at the use of antipsychotics among assisted living residents with dementia after a study found wide variations in prescribing patterns.
Care use, financial burden increase over time for elders with dementia
Oct 16, 2023
Increases were seen in care hours from family and unpaid helpers, use of in-home medical care, hospital stay and use of a nursing facility.
Pharmaceutical company to pay $96 million to settle claims of promoting unapproved use of drug for dementia...
By
Lois A. Bowers
Sep 27, 2019
Pharmaceutical company Avanir has agreed to pay $96 million to resolve federal False Claims Act allegations that it paid kickbacks and marketed the drug Nuedexta in long-term care communities for the off-label...
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Brain imaging company teases tech that will analyze side effects of new dementia drugs
By
Aaron Dorman
Nov 28, 2023
AI-enabled brain imaging technology will be launched next year to evaluate the side effects of new Alzheimer’s and dementia drugs.
Dementia to cost nation $321 billion this year, Alzheimer’s Association says
By
Kimberly Bonvissuto
Mar 16, 2022
This year, Alzheimer’s and other dementias will cost the nation $321 billion, increasing to $1 trillion by 2050, according to a report released Tuesday by the Alzheimer’s Association.